Salesforce, Informatica reportedly can't agree to deal terms
By Mike Murphy
Salesforce Inc.'s bid to buy Informatica Inc. has sputtered after neither company could agree to terms, the Wall Street Journal reported Sunday night.
Bloomberg News confirmed the report, saying the companies have not been able to agree on a price.
The deal, which could have been valued around $10 billion, would have been among Salesforce's largest acquisitions, but had run into opposition from analysts and investors.
Neither Salesforce nor Informatica immediately replied to requests for comment Sunday night.
Salesforce stock (CRM) rose 3.5% in premarket trading on Monday, while Informatica shares (INFA) tumbled 6%.
The Journal first reported Salesforce was closing in on the deal on April 12, and Salesforce stock has sunk about 8% since then, while Informatica shares have dropped about 8.5%.
Wall Street analysts expressed concerns over the deal, worrying it indicated Salesforce was pivoting back toward a growth strategy rather than maximizing profitability. It could have also signified a return to Salesforce's old M&A habits, which have had a spotty track record and drew the ire of activist shareholders last year.
There were also concerns that Salesforce, which specializes in business software, would be duplicating some of its product lines in absorbing Informatica, which makes data-management software.
Informatica co-founder Gaurav Dhillon last week called a potential acquisition a bad match.
Salesforce shares have fallen about 12% over the past month, but are up 2.8% year to date, while Informatica shares are down 4% in the past month and up 24% year to date.
-Mike Murphy
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-22-24 0518ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks